| Entry |
|
|---|
| Name |
Abatacept (USAN/INN);
Abatacept (genetical recombination) (JAN);
Orencia (TN) |
|---|
| Product |
|
|---|
| Sequence |
MGVLLTQRTL LSLVLALLFP SMASMAMHVA QPAVVLASSR GIASFVCEYA SPGKATEVRV
TVLRQADSQV TEVCAATYMM GNELTFLDDS ICTGTSSGNQ VNLTIQGLRA MDTGLYICKV
ELMYPPPYYL GIGNGTQIYV IDPEPCPDSD QEPKSSDKTH TSPPSPAPEL LGGSSVFLFP
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS
VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS
LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS
CSVMHEALHN HYTQKSLSLS PGK (Dimer: 146) |
|---|
| Type |
Peptide |
|---|
| Remark |
| Therapeutic category: | 3999 |
|
|---|
| Efficacy |
Antirheumatic |
|---|
| Disease |
Rheumatoid arthritis [DS: H00630] Juvenile idiopathic arthritis [DS: H01672] Psoriatic arthritis [DS: H01507] |
|---|
| Comment |
Abatacept is a fusion protein composed of an immunoglobulin fused to the extracellular domain of CTLA-4.
Abatacept binds to CD80/86, to inhibit the CD28 costimulatory signal.
Treatment of autoimmune diseases such as rheumatoid arthritis (selective co-stimulation modulator, binds to the B7 family of molecules expressed on antigen-presenting cells (APC))
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04672 | Intestinal immune network for IgA production |
|
|---|
| Interaction |
|
|---|
| Structure map |
| map07050 | Antirheumatics - DMARDs and biological agents |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AA Selective immunosuppressants
L04AA24 Abatacept
D03203 Abatacept (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
Selective T-cell costimulation modulators
Abatacept
D03203 Abatacept (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D03203 Abatacept (USAN/INN); Abatacept (genetical recombination) (JAN)
Target-based classification of drugs [BR:br08310]
Cell surface molecules and ligands
Other cell surface molecules
CD molecules
CD80
D03203 Abatacept (USAN/INN) <JP/US>
CD86
D03203 Abatacept (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03203
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03203
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03203
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03203
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
